购物车
- 全部删除
- 您的购物车当前为空
UPGL00004 是一种有效的谷氨酰胺酶 C (GAC) 抑制剂 ,其 IC50为29 nM。UPGL00004 对 GAC 的 Kd 为27 nM。UPGL00004 对高度侵袭性三阴性乳腺癌细胞系的增殖具有很强的抑制作用 。
为众多的药物研发团队赋能,
让新药发现更简单!
UPGL00004 是一种有效的谷氨酰胺酶 C (GAC) 抑制剂 ,其 IC50为29 nM。UPGL00004 对 GAC 的 Kd 为27 nM。UPGL00004 对高度侵袭性三阴性乳腺癌细胞系的增殖具有很强的抑制作用 。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 189 | 现货 | |
5 mg | ¥ 448 | 现货 | |
10 mg | ¥ 798 | 现货 | |
25 mg | ¥ 1,590 | 现货 | |
50 mg | ¥ 2,350 | 现货 | |
100 mg | ¥ 3,430 | 现货 | |
1 mL x 10 mM (in DMSO) | ¥ 526 | 现货 |
产品描述 | UPGL00004 is a potent glutaminase C (GAC) inhibitor with an IC50 of 29 nM. Kd of UPGL00004 for GAC was 27 nM. UPGL00004 has a strong inhibitory effect on the proliferation of highly aggressive triple negative breast cancer cell lines. |
靶点活性 | Glutaminase C:(kd)27 nM, Glutaminase C:29 nM, Glutaminase C:27 nM(kd), Glutaminase C:29 nM |
体外活性 | UPGL00004 inhibits MDA-MB-231, HS578T, and TSE cells (IC50s: 70, 129, and 262 nM, respectively).[1] |
体内活性 | In a triple-negative breast cancer patient-derived tumor graft model, the combination of UPGL00004 (1 mg/kg body weight) and Bevacizumab (2.5 mg/kg body weight) via intraperitoneal injection completely prevent any detectable increase in tumor size.[1] |
分子量 | 534.66 |
分子式 | C25H26N8O2S2 |
CAS No. | 1890169-95-5 |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
溶解度信息 | DMSO: 112.5 mg/mL (210.4 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
DMSO
|
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.